Sleep-Disordered Breathing in Context: Obstructive and Central Mechanisms, Symptoms, and Treatment Strategies for Adults

Sleep-disordered breathing (SDB) describes a spectrum of abnormalities in airflow and breathing during sleep, most commonly obstructive sleep apnea (OSA), but also central sleep apnea (CSA) and related hypoventilation syndromes. SDB is clinically important because it links disturbed sleep architecture with systemic consequences including cardiovascular morbidity, metabolic dysregulation, cognitive impairment, and impaired daytime functioning. The core pathophysiology differs by type: OSA is driven by upper-airway collapsibility during sleep, whereas CSA reflects impaired respiratory drive from central nervous system regulation. Across phenotypes, recurrent episodes of hypoxemia and intermittent hypercapnia activate sympathetic pathways, stimulate oxidative stress and inflammatory cascades, and fragment sleep.

In OSA, upper-airway collapse occurs when negative intrathoracic pressure generated by diaphragmatic effort during inspiration overcomes the neuromuscular stabilization of the pharyngeal airway. Multiple anatomic and functional factors contribute, including reduced pharyngeal dilator muscle activity, craniofacial structure, obesity-related fat deposition around the upper airway, and nasal resistance. During apneic events, oxygen saturation falls and carbon dioxide rises, promoting arousal and airway reopening. This cycle—obstruction, desaturation, sympathetic surge, and arousal—produces non-restorative sleep.

Clinically, OSA presents with loud snoring, witnessed apneas, nocturnal choking or gasping, and excessive daytime sleepiness. However, symptoms can be subtle or variable: insomnia, morning headaches, dry mouth, nocturia, irritability, and reduced concentration may predominate. Children and adults differ in typical manifestations, and some individuals exhibit minimal subjective sleepiness despite significant disease burden, an important diagnostic pitfall.

Central sleep apnea involves reduced ventilatory drive leading to periods of absent respiratory effort. CSA may be associated with heart failure, stroke, opioid use, high altitude exposure, and treatment-emergent apnea after initiation of positive airway pressure. Whereas OSA is characterized by airway obstruction with inspiratory effort, CSA shows diminished or absent effort during the central event. Instability in chemoreflex control—often conceptualized as loop gain—can cause over-ventilation and subsequent under-ventilation, producing periodic breathing.

Hypopneas and apneas are defined by airflow reduction and associated oxygen desaturation and/or arousal. The apnea-hypopnea index (AHI) quantifies event frequency, but diagnostic decisions must integrate symptoms and comorbidities. Polysomnography remains the diagnostic gold standard, capturing airflow, respiratory effort, oxygen saturation, electroencephalography, and limb movements. In selected patients, home sleep apnea testing can be appropriate for high pretest probability OSA, though it may not reliably assess CSA or hypoventilation.

Untreated SDB increases risk for hypertension, coronary artery disease, atrial fibrillation, stroke, and type 2 diabetes. Mechanistically, intermittent hypoxia and arousals drive endothelial dysfunction, sympathetic activation, and dysregulated glucose metabolism. Sleep fragmentation also impairs attention and executive function, increases accident risk, and can worsen mood symptoms.

Management is phenotype-specific but often begins with risk factor modification: weight reduction for overweight or obesity, avoidance of alcohol close to bedtime, smoking cessation, and careful review of sedating medications. For OSA, continuous positive airway pressure (CPAP) is the most established therapy, maintaining airway patency via pneumatic splinting. Adherence challenges—mask discomfort, nasal congestion, claustrophobia—can reduce effectiveness, so patient education, mask fitting, humidification, and behavioral support are critical.

Alternative therapies include oral appliance therapy using mandibular advancement devices for mild to moderate OSA or for patients intolerant of CPAP. Positional therapy may help those with supine-predominant disease. In selected cases, surgical interventions or hypoglossal nerve stimulation can be considered after anatomic evaluation and standard criteria.

For CSA, treatment focuses on underlying contributors such as optimizing heart failure therapy, reducing opioid exposure, addressing stroke-related control issues, and correcting reversible physiologic stressors. Positive airway pressure strategies may be used, and adaptive servo-ventilation has specific indications and contraindications, particularly in certain heart failure populations. Supplemental oxygen or acetazolamide may be considered in periodic breathing or altitude-related CSA under clinician supervision.

Because symptoms overlap across sleep and psychiatric disorders, careful assessment is essential. Persistent daytime fatigue, depression-like symptoms, or cognitive changes may reflect SDB rather than primary mood pathology. A structured evaluation should include history of snoring and witnessed apneas, review of medications, cardiovascular risk profiling, and sleep schedule assessment. When SDB is suspected, diagnostic testing and targeted therapy can markedly improve sleep quality, quality of life, and downstream health outcomes.

Source: @eighteyesinc (X/Twitter) Jul 25, 2026